Literature DB >> 26581778

Simple method for purification of enterotoxigenic Escherichia coli fimbriae.

Brittany Curtis1, Christen Grassel1, Rachel S Laufer1, Khandra T Sears2, Marcela F Pasetti2, Eileen M Barry1, Raphael Simon3.   

Abstract

Enterotoxigenic Escherichia coli (ETEC) are endemic pathogens in the developing world. They frequently cause illness in travelers, and are among the most prevalent causes of diarrheal disease in children. Pathogenic ETEC strains employ fimbriae as adhesion factors to bind the luminal surface of the intestinal epithelium and establish infection. Accordingly, there is marked interest in immunoprophylactic strategies targeting fimbriae to protect against ETEC infections. Multiple strategies have been reported for purification of ETEC fimbriae, however none is ideal. Purification has typically involved the use of highly virulent wild-type strains. We report here a simple and improved method to purify ETEC fimbriae, which was applied to obtain two different Class 5 fimbriae types of clinical relevance (CFA/I and CS4) expressed recombinantly in E. coli production strains. Following removal from cells by shearing, fimbriae proteins were purified by orthogonal purification steps employing ultracentrifugation, precipitation, and ion-exchange membrane chromatography. Purified fimbriae demonstrated the anticipated size and morphology by electron microscopy analysis, contained negligible levels of residual host cell proteins, nucleic acid, and endotoxin, and were recognized by convalescent human anti-sera.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Escherichia coli; Fimbriae; Purification

Mesh:

Substances:

Year:  2015        PMID: 26581778      PMCID: PMC4721563          DOI: 10.1016/j.pep.2015.11.007

Source DB:  PubMed          Journal:  Protein Expr Purif        ISSN: 1046-5928            Impact factor:   1.650


  27 in total

1.  Evolutionary and functional relationships of colonization factor antigen i and other class 5 adhesive fimbriae of enterotoxigenic Escherichia coli.

Authors:  Ravi P Anantha; Annette L McVeigh; Lanfong H Lee; Mary K Agnew; Frederick J Cassels; Daniel A Scott; Thomas S Whittam; Stephen J Savarino
Journal:  Infect Immun       Date:  2004-12       Impact factor: 3.441

2.  Incidence, etiology, and impact of diarrhea among deployed US military personnel in support of Operation Iraqi Freedom and Operation Enduring Freedom.

Authors:  Marshall R Monteville; Mark S Riddle; Usha Baht; Shannon D Putnam; Robert W Frenck; Kenneth Brooks; Manal Moustafa; Jaime Bland; John W Sanders
Journal:  Am J Trop Med Hyg       Date:  2006-10       Impact factor: 2.345

3.  Induction and evasion of host defenses by type 1-piliated uropathogenic Escherichia coli.

Authors:  M A Mulvey; Y S Lopez-Boado; C L Wilson; R Roth; W C Parks; J Heuser; S J Hultgren
Journal:  Science       Date:  1998-11-20       Impact factor: 47.728

4.  Milk immunoglobulin with specific activity against purified colonization factor antigens can protect against oral challenge with enterotoxigenic Escherichia coli.

Authors:  D J Freedman; C O Tacket; A Delehanty; D R Maneval; J Nataro; J H Crabb
Journal:  J Infect Dis       Date:  1998-03       Impact factor: 5.226

5.  CfaE tip mutations in enterotoxigenic Escherichia coli CFA/I fimbriae define critical human intestinal binding sites.

Authors:  K K Baker; M M Levine; J Morison; A Phillips; E M Barry
Journal:  Cell Microbiol       Date:  2009-01-15       Impact factor: 3.715

6.  Further characterization of delta aroA delta virG Shigella flexneri 2a strain CVD 1203 as a mucosal Shigella vaccine and as a live-vector vaccine for delivering antigens of enterotoxigenic Escherichia coli.

Authors:  F R Noriega; G Losonsky; J Y Wang; S B Formal; M M Levine
Journal:  Infect Immun       Date:  1996-01       Impact factor: 3.441

7.  Non-replicating oral whole cell vaccine protective against enterotoxigenic Escherichia coli (ETEC) diarrhea: stimulation of anti-CFA (CFA/I) and anti-enterotoxin (anti-LT) intestinal IgA and protection against challenge with ETEC belonging to heterologous serotypes.

Authors:  D G Evans; D J Evans; A R Opekun; D Y Graham
Journal:  FEMS Microbiol Immunol       Date:  1988-12

8.  Donor strand complementation governs intersubunit interaction of fimbriae of the alternate chaperone pathway.

Authors:  Steven T Poole; Annette L McVeigh; Ravi P Anantha; Lanfong H Lee; Yasemin M Akay; Emily A Pontzer; Daniel A Scott; Esther Bullitt; Stephen J Savarino
Journal:  Mol Microbiol       Date:  2007-03       Impact factor: 3.501

9.  Immune responses elicited against multiple enterotoxigenic Escherichia coli fimbriae and mutant LT expressed in attenuated Shigella vaccine strains.

Authors:  Eileen M Barry; Zeev Altboum; Genevieve Losonsky; Myron M Levine
Journal:  Vaccine       Date:  2003-01-17       Impact factor: 3.641

10.  Sentinel surveillance for travellers' diarrhoea in primary care.

Authors:  Gemma Northey; Meirion R Evans; Tinnu S Sarvotham; Daniel R Thomas; Tony J Howard
Journal:  BMC Infect Dis       Date:  2007-11-06       Impact factor: 3.090

View more
  3 in total

1.  Bioactive Immune Components of Anti-Diarrheagenic Enterotoxigenic Escherichia coli Hyperimmune Bovine Colostrum Products.

Authors:  Khandra T Sears; Sharon M Tennant; Mardi K Reymann; Raphael Simon; Nicky Konstantopoulos; William C Blackwelder; Eileen M Barry; Marcela F Pasetti
Journal:  Clin Vaccine Immunol       Date:  2017-08-04

2.  Impact of CD4+ T Cell Responses on Clinical Outcome following Oral Administration of Wild-Type Enterotoxigenic Escherichia coli in Humans.

Authors:  Monica A McArthur; Wilbur H Chen; Laurence Magder; Myron M Levine; Marcelo B Sztein
Journal:  PLoS Negl Trop Dis       Date:  2017-01-19

3.  A bivalent vaccine confers immunogenicity and protection against Shigella flexneri and enterotoxigenic Escherichia coli infections in mice.

Authors:  Pedro Henrique Q S Medeiros; David T Bolick; Solanka E Ledwaba; Glynis L Kolling; Deiziane V S Costa; Reinaldo B Oriá; Aldo Ângelo M Lima; Eileen M Barry; Richard L Guerrant
Journal:  NPJ Vaccines       Date:  2020-03-27       Impact factor: 7.344

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.